Unome Shinji, Imai Kenji, Miwa Takao, Hanai Tatsunori, Suetsugu Atsushi, Takai Koji, Suzui Natsuko, Miyazaki Tatsuhiko, Shimizu Masahito
Department of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Japan.
Department of Pathology, Gifu University, Japan.
Intern Med. 2024 Oct 1;63(19):2631-2636. doi: 10.2169/internalmedicine.3071-23. Epub 2024 Mar 4.
Combined hepatocellular cholangiocarcinoma is a rare and challenging primary liver malignancy that lacks any established standard treatments for unresectable cases. We herein present the first known case of a 49-year-old woman diagnosed with unresectable combined hepatocellular-cholangiocarcinoma, who underwent novel chemotherapy involving durvalumab plus tremelimumab combination therapy. The treatment was temporarily discontinued owing to immune-related adverse events, such as rash, and the patient was subsequently managed with systemic steroid therapy; however, the disease progressed after two courses of this treatment. Further studies are needed to validate the efficacy and safety of immune checkpoint inhibitors such as durvalumab and tremelimumab for the treatment of unresectable combined hepatocellular cholangiocarcinoma.
肝内胆管癌是一种罕见且具有挑战性的原发性肝脏恶性肿瘤，对于无法切除的病例，目前尚无既定的标准治疗方法。我们在此报告首例已知的49岁女性被诊断为无法切除的肝内胆管癌病例，该患者接受了包括度伐利尤单抗联合曲美木单抗的新型化疗。由于出现皮疹等免疫相关不良事件，治疗暂时中断，随后患者接受了全身类固醇治疗；然而，在两个疗程的这种治疗后疾病仍进展。需要进一步研究来验证度伐利尤单抗和曲美木单抗等免疫检查点抑制剂治疗无法切除的肝内胆管癌的疗效和安全性。
